title: Neurological soft signs, clinical symptoms and treatment reactivity in patients suffering from first episode schizophrenia.
abstract: OBJECTIVE
  (a) To investigate the correlation between clinical symptoms and neurological soft signs in patients suffering from their first episode of schizophrenia and (b) to examine the relationship between soft signs and the reactivity of first episode treatment.
  
  
  METHODS
  The trial included 92 male patients undergoing a first episode of schizophrenia. The clinical symptoms of the patients were rated on the positive and negative syndrome scale (PANSS). The PANSS scale was used to provide a measure for three syndromes: psychomotor poverty, disorganisation, and reality distortion. Neurological soft signs were assessed with the help of the neurological evaluation scale.
  
  
  RESULTS
  The findings corroborated significant positive correlations between soft neurological signs on the one hand and negative symptoms and reduced treatment response on the other.
  
  
  CONCLUSIONS
  Our study of the population of patients with first episode schizophrenia has corroborated the findings of those trials that found a correlation between neurological soft signs and the negative symptomatic dimension of schizophrenia. Another finding of the trial is that neurological soft signs were associated with poorer response to treatment of the first episode of schizophrenia.
authors.affiliation: Department of Psychiatry, Masaryk University, Faculty of Medicine and Faculty Hospital, Brno, Jihlavska 20, 625 00 Brno, Czech Republic. radovan.prikryl@post.cz
authors.forename: Radovan
authors.initials: R
authors.lastname: Prikryl
authors.forename: Eva
authors.initials: E
authors.lastname: Ceskova
authors.forename: Tomas
authors.initials: T
authors.lastname: Kasparek
authors.forename: Hana
authors.initials: H
authors.lastname: Kucerova
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001921:Brain / Q000503:physiopathology*; D002746:Chlorpromazine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009460:Neurologic Examination; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires
chemical_list: D014150:Antipsychotic Agents; D002746:Chlorpromazine